Peter E. Clark MDAssociate Professor, Urologic Surgery; Residency Program Director, Vanderbilt University Medical Center, Nashville, Tennessee
Dr. Clark received his undergraduate degree in Biology from Cornell University and went on to complete his medical degree at Harvard Medical School. He completed his urologic residency at the Cleveland Clinic Foundation and subsequently did his urologic oncology fellowship training at the University of Southern California. He is currently Professor and Chairman of the Department of Urology at Carolinas Healthcare System and Chair of Urologic Oncology at the Levine Cancer Institute in Charlotte NC, having moved from Vanderbilt University where he was also the Residency Program Director. Dr. Clark has an active clinical practice focused primarily on bladder and kidney cancer as well as an active interest in the basic sciences, particularly the role of MAPK’s and canonical Wnt signaling on kidney and bladder oncogenesis. Until recently he was Chair of the bladder/Penile cancer guidelines panel for the National Comprehensive Cancer Network (NCCN) and is a member of non-muscle invasive bladder cancer and small renal mass guidelines panels for the American Urologic Association (AUA). He is serving as the representative for the Southeast Section of the AUA to the AUA Foundation Research Council, the Research, Education, and Communication Committee, the Judicial and Ethics Committee, the Practice Guidelines Committee (where he serves as Vice Chairman), and is on the editorial boards for the Journal of Urology, BJUI, Urologic Oncology, and UROLOGY. He serves on the Examination Committee for the American Board of Urology. He is also an active member of the Society of Urologic Oncology (where he recently was chair of the Fellowship Committee), The Society of Academic Urologists, and the Society of Basic Urologic Research. He has over 170 publications in both the clinical and basic sciences.
DisclosuresDr. Clark reports no diclosures.
Recent Contributions to PracticeUpdate:
- FGFR Alterations and FGFR mRNA Expression as Prognostic Indicators in Metastatic Urothelial Cancer Treated With Checkpoint Inhibitors
- Differential Tumor Subtypes of T1 Bladder Cancer
- Long-Term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma
- Renal Fossa Recurrence After Radical Nephrectomy
- Impact of Arsenic Exposure on Clinicopathological Characteristics of Bladder Cancer
- Validation of Neutrophil-to-Lymphocyte Ratio in Patients With T1G3 Non–Muscle Invasive Bladder Cancer
- Diagnostic Accuracy of MRI for Tumor Staging of Bladder Cancer
- Impact of Intraoperative Cyst Rupture During Partial Nephrectomy for Cystic Renal Masses
- Conservative Management After Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
- Discordance Between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma